Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations
The DOI matches its Crossref record; 344 of the 344 references it cites were found in a registry or an index.
Abstract
With the widespread use of atypical or second-generation antipsychotics, switching treatment has become current practice and more complicated, as the pharmacological profiles of these agents differ substantially despite their similarity in being 'atypical'. All share the ability to block dopamine D₂ receptors, and most of them also block serotonin 5-HT2A receptors. Apart from these common features, some atypical antipsychotics are also able to block or stimulate other dopamine or serotonin receptors, as well as histaminergic, muscarinergic or adrenergic receptors. As a result of the varying receptor affinities, in switching or discontinuing compounds several possible pitfalls have to be considered, including the occurrence of withdrawal and rebound syndromes. This article reviews the pharmacological background of functional blockade or stimulation of receptors of interest in regard to atypical antipsychotics and the implicated potential withdrawal and rebound phenomena. A MEDLINE search was carried out to identify information on withdrawal or rebound syndromes occurring after discontinuation of atypical antipsychotics. Using the resulting literature, we first discuss the theoretical background to the functional consequences of atypical antipsychotic-induced blockade or stimulation of neurotransmitter receptors and, secondly, we highlight the clinical consequences of this. We then review the available clinical literature on switching between atypical antipsychotics, with respect to the occurrence of withdrawal or rebound symptoms. Finally, we offer practical recommendations based on the reviewed findings. The systematic evaluation of withdrawal or rebound phenomena using randomized controlled trials is still understudied. Knowledge of pharmacological receptor-binding profiles may help clinicians in choosing adequate switching or discontinuation strategies for each agent. Results from large switching trials indicate that switching atypical antipsychotics can be performed in a safe manner. Treatment-emergent adverse events during or after switching are not always considered to be, at least in part, associated with the pre-switch antipsychotic. Further studies are needed to substantiate the evidence gained so far on different switching strategies. The use of concomitant medication, e.g., benzodiazepines or anticholinergic drugs, may help to minimize symptoms arising from the discontinuation or switching of antipsychotic treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [20]
In the citing paper
“Third, although the principal therapeutic effects of antipsychotics are attributed to D2 antagonism, other receptor targets, including 5HT2 and 5HT1A, have also been thought relevant, and these receptors, and others, such as cholinergic receptors, may also determine withdrawal effects.20”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [20]
In the citing paper
“Studies on withdrawal reactions associated with antipsychotics switch were extensively reviewed also by Cerovecki et al. [8] and similar conclusions were reached.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [8]
In the citing paper
“New withdrawal symptoms following dose decrease, discontinuation, or switch may occur with any type of antipsychotic and include a wide range of symptoms [8, 9] which are reported in Table 4.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [8]
In the citing paper
“Overall, SGAs are associated as frequently with new withdrawal symptoms as FGAs, when we take into consideration the early 1960-1970 studies of FGAs.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [8]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–344 of 344
Marcus, M. M., Wiker, C., Frånberg, O., Konradsson‐Geuken, Å., Langlois, X., Jardemark, K. E., & Svensson, T. H. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990794 · Cited by 60
Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia
Buchanan, R. W., Panagides, J., Zhao, J., Phiri, P., den Hollander, W., Ha, X., Kouassi, A., Alphs, L., Schooler, N., Szegedi, A., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f880a · Cited by 60
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.11.1395 · Cited by 59
Behavioural evaluation of cholinergic drugs
Iversen, S. D. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00059-3 · Cited by 59
Weight decline in patients switching from olanzapine to quetiapine
Gupta, S., Masand, P. S., Virk, S., Schwartz, T. L., Hameed, A., Frank, B. L., & Lockwood, K. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.016 · Cited by 59
Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia
Mori, K., Nagao, M., Yamashita, H., Morinobu, S., & Yamawaki, S. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.01.019 · Cited by 59
Lindenmayer, J.-P., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., Chakos, M., & McEvoy, J. P. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1011 · Cited by 59
Meyer, J. M., Pandina, G., Bossie, C. A., Turkoz, I., & Greenspan, A. J. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.12.005 · Cited by 59
Potkin, S. G., Ogasa, M., Cucchiaro, J. B., & Loebel, A. D. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.008 · Cited by 58
Switching From Clozapine to Olanzapine in Treatment-Refractory Schizophrenia
Henderson, D. C., Nasrallah, R. A., & GOFF, D. C. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1105 · Cited by 57
Mahmoud, R. A., Engelhart, L., Janagap, C. C., Oster, G., & Ollendorf, D. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424050-00004 · Cited by 57
Fallon, P., & Dursun, S. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109359097 · Cited by 56
The cerebellar norepinephrine system: inhibition, modulation, and gating
Woodward, D. J., Moises, H. C., Waterhouse, B. D., Yeh, H. H., & Cheun, J. E. (1991) · Progress in brain research · doi:10.1016/s0079-6123(08)63820-0 · Cited by 55
Appl, H., Holzammer, T., Dove, S., Haen, E., Straßer, A., & Seifert, R. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0704-0 · Cited by 55
Self-citationIntramuscular Paliperidone Palmitate
Hoy, S. M., Scott, L. J., & Keating, G. M. (2010) · CNS Drugs · doi:10.2165/11203810-000000000-00000 · Cited by 55
Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone
Still, D. J., Dorson, P. G., Crismon, M. L., & Pousson, C. (1996) · Psychiatric Services · doi:10.1176/ps.47.12.1382 · Cited by 54
Marinis, T., Saleem, P., Glue, P., Arnoldussen, W., Teijeiro, R., Lex, A., Latif, M., & Medori, R. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-992140 · Cited by 54
Dossenbach, M. R. K., Beuzen, J. N., Avnon, M., Belmaker, R. H., Elizur, A., Mark, M., Munitz, H., Schneidman, M., Shoshani, D., Kratky, P., et al. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80082-x · Cited by 54
Moriyama, N., Nasu, K., Takeuchi, T., Akiyama, K., Murata, S., Nishimatsu, H., Yano, J., Tsujimoto, G., & Kawabe, K. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701485 · Cited by 53
Pae, C., Serretti, A., Chiesa, A., Mandelli, L., Lee, C., Lee, C., Kim, J., Ronchi, D. D., & Paik, I. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.002 · Cited by 52
Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors
Michal, P., Lysı́ková, M., El‐Fakahany, E. E., & Tuček, S. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00341-6 · Cited by 52
Citrome, L. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.531259 · Cited by 51
Os, J. V., Bossie, C. A., & Lasser, R. A. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000122861.35081.16 · Cited by 50
Creed, M. C., Oraha, A., & Nóbrega, J. N. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.025 · Cited by 50
Is there a limbic system equivalent of tardive dyskinesia?
Davis, K. L., & Rosenberg, G. S. (1979) · PubMed · Cited by 50
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
Faries, D. E., Ascher‐Svanum, H., Nyhuis, A. W., & Kinon, B. J. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-54 · Cited by 48
5-HT1A receptor expression during memory formation
Luna‐Munguía, H., Apolinar, L. M., Rocha, L., & Meneses, A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2240-4 · Cited by 48
Kim, S.-W., Shin, I.-S., Kim, J.-M., Lee, J.-H., Lee, Y.-H., Yang, S.-J., & Yoon, J.-S. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31819a68b5 · Cited by 47 · cited 1×
“, cholinergic rebound after switch from clozapine [78, 86, 88, 94].”
BackgroundOhno, Y., Shimizu, S., Imaki, J., Ishihara, S., Sofue, N., Sasa, M., & Kawai, Y. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.005 · Cited by 47
Cortese, L., Caligiuri, M. P., Williams, R., Schieldrop, P., Manchanda, R., Malla, A., & Harricharan, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160864f · Cited by 47
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats
Turrone, P., Remington, G. J., Kapur, S., & Nóbrega, J. N. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.023 · Cited by 47
Effectiveness of Switching Antipsychotic Medications
Essock, S. M. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.12.2090 · Cited by 47
Schambra, U. B., Mackensen, G. B., Stafford‐Smith, M., Haines, D. E., & Schwinn, D. A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.021 · Cited by 46
Montes, J. M. G., Rodriguez, J. L., Balbo, E., Sopelana, P., Martín, E. E., Soto, J. A., Delgado, J. F., Díez, T., & Villardaga, I. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.002 · Cited by 45
Kalkman, H. O., Feuerbach, D., Loetscher, E., & Schoeffter, P. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00419-3 · Cited by 45
Lambert, T. J. R. (2007) · PubMed · Cited by 43
Mrzljak, L., Levey, A. I., & Rakic, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7337 · Cited by 43
Switching Clozapine Responders to Olanzapine
Littrell, K. H., Johnson, C. G., Hilligoss, N. M., Peabody, C. D., & Littrell, S. H. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1204 · Cited by 43
Shimizu, S., Tatara, A., Imaki, J., & Ohno, Y. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.005 · Cited by 42
Metabolic Impact of Switching Antipsychotic Therapy to Aripiprazole After Weight Gain: A Pilot Study
Kim, S. H., Ivanova, O., Abbasi, F. A., Lamendola, C. A., Reaven, G. M., & Glick, I. D. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3180a9076c · Cited by 42
Acute effects of histamine on plasma prolactin and luteinizing hormone levels in male rats
Donoso, A. O., & Bannza, A. M. (1976) · Journal of Neural Transmission · doi:10.1007/bf01248768 · Cited by 42
α1A‐Adrenoceptor‐mediated contractile responses of the human vas deferens
Furukawa, K., Rosario, D. J., Smith, D. J., Chapple, C. R., Uchiyama, T., & Chess‐Williams, R. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16380.x · Cited by 42
Binder, M. D., Mittoux, A., He, Y., & Peuskens, J. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0142-x · Cited by 41
Alptekın, K., Hafez, J., Brook, S., Akkaya, C., Tzebelikos, E., Üçok, A., tallawy, H. E., DANACI, A. E., Lowe, W., & Karayal, O. N. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832c2624 · Cited by 41
Clozapine-Withdrawal Catatonia
Wadekar, M., & Syed, S. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70710-6 · Cited by 41
The crossover approach to switching antipsychotics: What is the evidence?
Remington, G. J., Chue, P. S., Stip, É., Kopala, L. C., Girard, T. A., & Christensen, B. K. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.009 · Cited by 41
Knight, J. A., Smith, C., Toohey, N., Klein, M. T., & Teitler, M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.052084 · Cited by 41
Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.
Buckley, P. F. (2007) · PubMed · Cited by 40
Conley, R. R., Hirschfeld, R. M. A., Kelly, A. D. L., PharmD, & Bcpp (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4134 · Cited by 40
Ohno, Y., Shimizu, S., & Imaki, J. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08313fp · Cited by 40
Mørk, A., Witten, L. M., & Arnt, J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1578-4 · Cited by 40
Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone
Subramanian, N., & Kalkman, H. O. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00307-4 · Cited by 39
Rouse, S. T., & Levey, A. I. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19970414)380:3<382::aid-cne7>3.0.co;2-z · Cited by 39
Risk factors for the development of neuroleptic induced akathisia
Miller, C. H., Hummer, M., OBERBAUER, H., Kurzthaler, I., DeCol, C., & Fleischhacker, W. W. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00041-7 · Cited by 38
Switching to Olanzapine From Previous Antipsychotics
Lee, C., Conde, B. J. L., Mazlan, M., Visanuyothin, T., Wang, A., Wong, M. M. C., Walker, D. J., Roychowdhury, S. M., Wang, H., & Trân, P. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0706 · Cited by 38
Kim, S., Shin, I., Kim, J., Lee, S., Lee, Y., Yang, S., & Yoon, J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1057 · Cited by 38
Silva, J. A. C. E., Alvarez, N. P., Mazzotti, G., Gattaz, W. F., Ospina, J., Larach, V. W., STARKSTEIN, S. E., Oliva, D., Cousins, L., Tohen, M. F., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00004 · Cited by 38
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test
Ohno, Y., Shimizu, S., Imaki, J., Ishihara, S., Sofue, N., Sasa, M., & Kawai, Y. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.04.005 · Cited by 38
Real-Life Switching Strategies With Second-Generation Antipsychotics: (ASCP Corner)
Correll, C. U. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0122 · Cited by 37
Décossas, M., Bloch, B., & Bernard, V. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10734 · Cited by 37
Spurling, R. D., Lamberti, J. S., Olsen, D., Tu, X., & Tang, W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0308 · Cited by 37
Ganguli, R., Brar, J. S., Mahmoud, R. A., Berry, S. A., & Pandina, G. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-17 · Cited by 35
Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia
Kim, S., Shin, I., Kim, J., Bae, K., Yang, S., & Yoon, J. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d52b85 · Cited by 35
Switching Between Second-Generation Antipsychotics: Why and How?
Edlinger, M., Baumgartner, S., ller, N. E.-F., Hummer, M., & Fleischhacker, W. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00003 · Cited by 35
Jauß, M., Krack, P., Franz, M., Klett, R., Bauer, R., Gallhofer, B., & Dorndorf, W. (1996) · Movement Disorders · doi:10.1002/mds.870110621 · Cited by 33
Takeuchi, H., Suzuki, T., Uchida, H., Nakajima, S., Nomura, K., Kikuchi, T., Manki, H., Watanabe, K., & Kashima, H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181842586 · Cited by 33
Dossenbach, M. R. K., Kratky, P., Schneidman, M., Grundy, S. L., Metcalfe, S., Tollefson, G. D., & Belmaker, R. H. (2001) · PubMed · Cited by 32
Svensson, T. H., & Str�mbom, U. (1977) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00508642 · Cited by 32
Changing antipsychotic medication: guidelines on the transition to treatment with Risperidone
Borison, R. L. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80211-6 · Cited by 32
Rossi, A., Vita, A., Tiradritti, P., & Romeo, F. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f94905 · Cited by 32
Coruzzi, G., Pozzoli, C., Adami, M., Grandi, D., Guido, N., Smits, R. A., de Esch, I. J. P., & Leurs, R. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01396.x · Cited by 32
Studies on the cardiovascular actions of central histamine H1 and H2 receptors
Poulakos, J. J., & Gertner, S. B. (1990) · Journal of Cardiothoracic Anesthesia · doi:10.1016/0888-6296(90)90263-f · Cited by 32
Prolonged Psychotic Relapse After Abrupt Clozapine Withdrawal
Parsa, M. A., AL-LAHHAM, Y. H., Ramirez, L. F., & Meltzer, H. Y. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199304000-00012 · Cited by 31
Early relapse after sudden withdrawal or dose reduction of clozapine
Per�nyi, A., Kuncz, E., & Bagdy, G. (1985) · Psychopharmacology · doi:10.1007/bf00431719 · Cited by 31
Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia
Reynolds, G. P. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05830.x · Cited by 31
Conversions From Clozapine to Other Antipsychotic Drugs
Gardner, D. M. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240089014 · Cited by 31
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
Alphs, L. D., & Lee, H. S. (1991) · PubMed · Cited by 31
Ganesan, S., Agambaram, V., Randeree, F., Eggens, I., Huizar, K., Meuliend, D., & on behalf of the Study 147 investigators (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253384 · Cited by 30
Cosi, C., & Koek, W. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01493-5 · Cited by 30
Malmberg‐Aiello, P., Lamberti, C., Ipponi, A., Hänninen, J., Ghelardini, C., & Bartolini, A. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00004954 · Cited by 30
Larmo, I., de Nayer, A., Windhager, E., Irmansyah, Lindenbauer, B., Rittmannsberger, H., Platz, T., Jones, A., & Altman, C. A. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.723 · Cited by 30
Serotonin 1A Receptors in Memory Function
Sumiyoshi, T., & Meltzer, H. Y. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1505 · Cited by 30
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.
Llorca, P., Vaïva, G., & Lançon, C. (2001) · PubMed · Cited by 30
Chen, C., Lin, T., Wang, C., & Shuai, H. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02156.x · Cited by 28
Short‐term safety and pharmacokinetic profile of asenapine in older patients with psychosis
Dubovsky, S. L., Frobose, C., Phiri, P., de Greef, R., & Panagides, J. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2737 · Cited by 27
Serotonin Receptors of Type 6 (5-HT6): What can we Expect from them?
Marazziti, D., Baroni, S., Dell’Osso, M. C., Bordi, F., & Borsini, F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011283 · Cited by 27
Ryckmans, V., Kahn, J., Modell, S., Werner, C., McQuade, R., Kerselaers, W., Lissens, J., & Sanchez, R. (2009) · Pharmacopsychiatry · doi:10.1055/s-0028-1112134 · Cited by 27
Lin, C.-C., Bai, Y., Wang, Y.-C., Chen, T., Lai, I., Chen, J., Chen, S., Gau, S. S., & Liou, Y. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bf613e · Cited by 27
Emerging treatments in the management of schizophrenia – focus on sertindole
Zoccali, R. A. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6591 · Cited by 27
Franowicz, J. S., & Arnsten, A. F. T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1110-6 · Cited by 26
Takahashi, H., Kamata, M., Yoshida, K., Ishigooka, J., & Higuchi, H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1013 · Cited by 26
Clozapine Withdrawal: Serotonergic or Dopaminergic Mechanisms?
Meltzer, H. Y. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200094013 · Cited by 26
Clozapine as a drug of dependence
Goudie, A. J., Smith, J. A., Robertson, A., & Cavanagh, C. (1999) · Psychopharmacology · doi:10.1007/s002130050901 · Cited by 25
The Effect of Sudden Clozapine Discontinuation on Management of Schizophrenic Patients
Miodownik, C., Lerner, V., Kibari, A., Todder, D., & Cohen, H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0805 · Cited by 24
Switching From Depot Antipsychotic Drugs to Olanzapine in Patients With Chronic Schizophrenia
Godleski, L., Goldsmith, L. J., Vieweg, W. V. R., Zettwoch, N. C., Stikovac, D., & Lewis, S. J. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0203 · Cited by 24
Histaminergic Neuron System: Morphological Features and Possible Functions
Wada, H., Inagaki, N., Itowi, N., & Yamatodani, A. (1991) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7309-3_1 · Cited by 24
Withdrawal symptoms after long-term treatment with low-potency neuroleptics.
Chouinard, G., Bradwejn, J., Annable, L., Jones, B. D. M., & Ross‐Chouinard, A. (1984) · PubMed · Cited by 23
ANALYSIS OF HISTAMINE RECEPTORS IN THE CENTRAL THERMOREGULATORY MECHANISM OF Mastomys natalensis
Dhawan, B. N., Shukla, R., & Srimal, R. C. (1982) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1982.tb08767.x · Cited by 23
Möller, H., Johnson, S., Mateva, T., Brecher, M., Svensson, O., Miller, F., & Meulien, D. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2d42c · Cited by 23
Unexpected Dystonia While Changing From Clozapine to Risperidone
Radford, J. M., Brown, T. M., & Borison, R. L. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00015 · Cited by 23
Kim, C. Y., Chung, S., Lee, J.-N., Kwon, J. S., Kim, D., Kim, C. E., Jeong, B., Jeon, Y., Lee, M.-S., Jun, T., et al. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832c25d7 · Cited by 22
A Decade of Progress in the Discovery and Development of ‘Atypical’ Antipsychotics
Macdonald, G. J., & Bartolomé, J. M. (2010) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(10)49002-5 · Cited by 21
Kluge, M., Wehmeier, P. M., Dittmann, R. W., Länger, F. P., Czekalla, J., Lehmann, M., Keßler, F., Beyenburg, S., & Naber, D. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837764 · Cited by 21
Histamine H3-Receptor Inverse Agonists as Novel Antipsychotics
Ito, C. (2009) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152409788452036 · Cited by 21
Observations on switching patients with schizophrenia to risperidone treatment
Kirov, G., Murray, R. M., Seth, R. V., Feeney, S. T., & the Risperidone Switching Study Group (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09659.x · Cited by 21
Prinssen, E. P. M., Koek, W., Colpaert, F. C., & Kleven, M. S. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00013 · Cited by 21
Imaki, J., Mae, Y., Shimizu, S., & Ohno, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.001 · Cited by 19
Ganguli, R., Brar, J., Garbut, R., Chang, C.-C., & Basu, R. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.2.3 · Cited by 19
Linden, M., Scheel, T., & Eich, F. X. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106061154 · Cited by 19
Hawley, C. J., Turner, M. R., Latif, M. A., Curtis, V. A., Saleem, P. T., & Wilton, K. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1085 · Cited by 19
Switching from Quetiapine to Ziprasidone
Karayal, O. N., Glue, P., Bachinsky, M., Stewart, M., Chappell, P. B., Kolluri, S., & Çavuş, I. (2011) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000396061.05269.c8 · Cited by 18
Nakajima, M., Terao, T., Iwata, N., & Nakamura, J. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837766 · Cited by 17
Stip, É., Zhornitsky, S., Potvin, S., & Tourjman, V. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.010 · Cited by 17
Clozapine-olanzapine: a potentially dangerous switch. A report of two cases
Delassus-Guenault, N., Jegouzo, A., Odou, P., Seguret, T., Zangerlin, H., Vignole, E., & Robert, H. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00218.x · Cited by 17
Thoolen, M. J. M. C., Hendriks, J. C. A., Timmermans, P. B. M. W. M., & van Zwieten, P. A. (1983) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198303000-00010 · Cited by 17
Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects
Perquin, L. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200511000-00010 · Cited by 17
Faries, D. E., Ascher‐Svanum, H., Nyhuis, A. W., & Kinon, B. J. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x297385 · Cited by 16
Proposed strategies for successful clinical management with aripiprazole
Mago, R. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1279 · Cited by 16
Predictors of Early Worsening after Switch to Aripiprazole
Pae, C., Chiesa, A., Mandelli, L., Patkar, A. A., Gibiino, S., & Serretti, A. (2010) · Clinical Drug Investigation · doi:10.2165/11533060-000000000-00000 · Cited by 14
Lu, Z., Hu, J., Chen, C., Lan, T., Diokno Gregorio, L., Lee, B. Y., McElroy, H. J., Harrison, G., & Ang, Q. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.006 · Cited by 14
Switching of antipsychotics to aripiprazole in the treatment of schizophrenia.
Lin, H., Chong, M., Lee, Y., Yeh, W., & Lin, P. (2009) · PubMed · Cited by 14
Commentary on strategies for switching antipsychotics
Davis, J. M., & Leucht, S. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-18 · Cited by 13
Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone
Rossi, A., Cañas, F., Fagiolini, A. M., Larmo, I., Levy, P., Montes, J. M. G., Papageorgiou, G., Sturlason, R., Zink, M., & Correll, C. U. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2255 · Cited by 13
Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine.
Da, S., & Hm, S. (1996) · PubMed · Cited by 13
MALLA, A. K., Norman, R. M. G., Kotteda, V., & Zirul, S. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80003-4 · Cited by 12
Olanzapine withdrawal/discontinuation-induced hyperthermia in rats
Goudie, A. J., Cole, J. C., & Sumnall, H. R. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.007 · Cited by 12
Clozapine Withdrawal Symptoms after Change to Sertindole in a Schizophrenic Patient
Berecz, R., Glaub, T., Kellermann, M., de la Rubia, A., LLerena, A., & Degrell, I. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-7963 · Cited by 12
Clozapine-Withdrawal Catatonia
Wadekar, M., & Syed, S. (2010) · Psychosomatics · doi:10.1176/appi.psy.51.4.355 · Cited by 12
Use of Aripiprazole in treatment resistant schizophrenia
Hughes, D., & Morcos, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083850 · Cited by 11
Sarin, A., Nagpal, J., Bohra, N., Jiloha, R. C., Rao, G. P., Sharma, S. K., Vaishnav, M., Vaya, L., Karan, R. S., Patel, N. K., et al. (2004) · PubMed Central · Cited by 10
Hanisch, F., Friedemann, J., & Pillmann, F. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109348159 · Cited by 10
Ganesan, S., Agambaram, V., Randeree, F., Eggens, I., Huizar, K. K. J. F., Meulien, D., & Study 147 Investigators (2008) · Current Medical Research and Opinion · doi:10.1185/030079907x253384 · Cited by 10
Labelle, A., Bourget, D., Boulay, L. J., Ellis, J., & Tessier, P. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00003 · Cited by 9
Kuloğlu, M., Ekinci, O., Albayrak, Y., & Çayköylü, A. (2010) · Archives of Women s Mental Health · doi:10.1007/s00737-010-0150-x · Cited by 8
Aripiprazole in Treatment-refractory Schizophrenia
Hsu, W., Lee, C.-I., Chiu, N., & Kahn, D. A. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000351883.75754.45 · Cited by 7
Emergence of Neuroleptic Malignant Syndrome While Switching Between Risperidone and Paliperidone
Teng, P., & Lane, H. (2011) · Journal of Neuropsychiatry · doi:10.1176/jnp.23.4.jnpe16 · Cited by 7
Scheifler, P. L., & Weiden, P. J. (2006) · PubMed · Cited by 6
Novick, D., Haro, J. M., Suarez, D. L., Teixeira, J. M., & Naber, D. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282ff5fed · Cited by 5
[The concept of supersensitivity psychosis. The particular case of clozapine].
Llorca, P., Penault, F., Lançon, C., Dufumier, E., & Vaïva, G. (1999) · PubMed · Cited by 5
Nakanishi, S., Kunugi, H., Murray, R. M., Nojima, S., Ogawa, T., & TAKAHASHI, T. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01591.x · Cited by 4
Introduction: the art and science of switching antipsychotic medications.
Buckley, P. F. (2007) · PubMed · Cited by 2
Improvement of Oral Dyskinesia After Switching From Aripiprazole to Paliperidone: A Case Report
Lai, C. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.3.e18 · Cited by 2
Emergence of Neuroleptic Malignant Syndrome While Switching Between Risperidone and Paliperidone
Teng, P., & Lane, H. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.4.e16 · Cited by 2
Review: no evidence to support gradual over abrupt switching of antipsychotics
Edlinger, M., & Fleischhacker, W. W. (2006) · Evidence-Based Mental Health · doi:10.1136/ebmh.9.1.10 · Cited by 1
Research works printed but not linked: 1
- Cucchiaro J, Potkin SG, Ogasa M, et al. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Bull. 2009;35(Suppl. 1):342–3.
Cited by
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
“In this scenario, unless cross-titration is used, and depending on the relative half-lives of the discontinued and the new drug, the patient can suffer from temporary underdosing or overdosing.(35,235)”
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Self-citation
Metadata
- Authors
- Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Vitos (DE)
- University of Regensburg (DE)
- University of Bonn (DE)
- Bệnh viện Đa khoa Xanh Pôn (VN)
- Corresponding author
- Musil, Richard
- Venue
- CNS Drugs
- Published
- 2013-07
- Volume
- 27
- Issue
- 7
- Pages
- 545-572
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2016329927
- Cited by
- 112
- References
- 341
- Citations by year
- 2026: 15 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 13 · 2019: 14 · 2018: 7 · 2017: 11 · 2016: 7 · 2015: 4 · 2014: 4 · 2013: 1
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- atypical antipsychotics, antipsychotic switching, antipsychotic discontinuation, withdrawal symptoms, dopamine D2 receptor blockade, receptor binding profiles, treatment-emergent adverse events, benzodiazepines, anticholinergic agents, schizophrenia
- MeSH terms
- Animals, Drug Administration Schedule, Humans, Psychoses, Substance-Induced, Substance Withdrawal Syndrome, Antipsychotic Agents, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.